📗 Cite This Artifact
AIFM1 Gene
AIFM1 Gene
Introduction
The AIFM1 gene (Apoptosis Factor, Mitochondria-Associated 1) encodes a crucial flavoprotein that plays dual roles in both normal mitochondrial function and programmed cell death. AIF is essential for oxidative phosphorylation and complex I assembly, while also serving as a key mediator of caspase-independent apoptosis.[@kruse2008] Mutations in AIFM1 cause severe neurodegenerative disorders, highlighting its critical importance in neuronal survival.[@ghezzi2010]
Overview
<div class="infobox infobox-gene">
<h3>AIFM1</h3>
<table>
<tr><th>Full Name</th><td>Apoptosis-Inducing Factor Mitochondria-Associated 1</td></tr>
<tr><th>Chromosomal Location</th><td>Xq26.1</td></tr>
<tr><th>NCBI Gene ID</th><td>[9131](https://www.ncbi.nlm.nih.gov/gene/9131)</td></tr>
<tr><th>OMIM</th><td>[300169](https://www.omim.org/entry/300169)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000156509</td></tr>
<tr><th>UniProt</th><td>[O95831](https://www.uniprot.org/uniprot/O95831)</td></tr>
<tr><th>Protein Class</th><td>Flavoprotein (FAD-binding)</td></tr>
<tr><th>Protein Size</th><td>613 amino acids (~63 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth Disease Type 4, Combined Oxidative Phosphorylation Deficiency, Parkinson's Disease, Alzheimer's Disease, X-Linked Mental Retardation</td></tr>
</table>
</div>
Protein Structure
AIF is a 613-amino acid flavoprotein with distinct structural domains:[@sevrioukov2022]
AIFM1 Gene
Introduction
The AIFM1 gene (Apoptosis Factor, Mitochondria-Associated 1) encodes a crucial flavoprotein that plays dual roles in both normal mitochondrial function and programmed cell death. AIF is essential for oxidative phosphorylation and complex I assembly, while also serving as a key mediator of caspase-independent apoptosis.[@kruse2008] Mutations in AIFM1 cause severe neurodegenerative disorders, highlighting its critical importance in neuronal survival.[@ghezzi2010]
Overview
<div class="infobox infobox-gene">
<h3>AIFM1</h3>
<table>
<tr><th>Full Name</th><td>Apoptosis-Inducing Factor Mitochondria-Associated 1</td></tr>
<tr><th>Chromosomal Location</th><td>Xq26.1</td></tr>
<tr><th>NCBI Gene ID</th><td>[9131](https://www.ncbi.nlm.nih.gov/gene/9131)</td></tr>
<tr><th>OMIM</th><td>[300169](https://www.omim.org/entry/300169)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000156509</td></tr>
<tr><th>UniProt</th><td>[O95831](https://www.uniprot.org/uniprot/O95831)</td></tr>
<tr><th>Protein Class</th><td>Flavoprotein (FAD-binding)</td></tr>
<tr><th>Protein Size</th><td>613 amino acids (~63 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>Charcot-Marie-Tooth Disease Type 4, Combined Oxidative Phosphorylation Deficiency, Parkinson's Disease, Alzheimer's Disease, X-Linked Mental Retardation</td></tr>
</table>
</div>
Protein Structure
AIF is a 613-amino acid flavoprotein with distinct structural domains:[@sevrioukov2022]
- N-terminal mitochondrial targeting sequence (MTS): First 50 amino acids direct mitochondrial import
- FAD-binding domain: Residues 150-400, binds FAD cofactor essential for NADH oxidase activity
- DNA-binding domain: C-terminal region (residues 400-613) can bind DNA in the nucleus
- Proline-rich region: Contains SH3-binding motifs for protein interactions
The mature protein (~62 kDa) is anchored to the inner mitochondrial membrane with the FAD-binding domain facing the intermembrane space.
Normal Cellular Functions
Oxidative Phosphorylation
AIF is essential for mitochondrial respiratory chain function:
- Complex I assembly: Critical for proper assembly and stability of NADH:ubiquinone oxidoreductase (Complex I)
- NADH oxidation: Functions as a NADH oxidase using FAD as cofactor, contributing to mitochondrial redox balance
- Mitochondrial DNA maintenance: Required for mitochondrial DNA (mtDNA) transcription and replication
- Iron-sulfur cluster biogenesis: Involved in assembly of Fe-S clusters essential for multiple mitochondrial enzymes
Apoptosis Induction
Under apoptotic conditions, AIF undergoes proteolytic processing:
- Calpain cleavage: Ca²⁺-dependent calpains cleave AIF at residue 1025, releasing it from the inner membrane
- Nuclear translocation: Cleaved AIF (tAIF, ~57 kDa) translocates to the nucleus in a PARP-1-dependent manner
- DNA fragmentation: tAIF promotes large-scale DNA fragmentation (50 kb fragments) through chromatin condensation
- Caspase-independent cell death: Mediates apoptosis even when caspase activity is blocked
Expression Pattern
- Tissue distribution: Highest expression in heart, brain, skeletal muscle, and liver
- Brain regions: Particularly high in neurons of the hippocampus, cerebral cortex, and basal ganglia
- Cellular localization: Mitochondrial inner membrane (primarily), with nuclear translocation during apoptosis
- Developmental expression: Essential for embryonic development; knockout is embryonic lethal in mice
Disease Associations
Charcot-Marie-Tooth Disease Type 4 (CMT4A2)
- Inheritance: X-linked recessive
- Mechanism: Loss-of-function mutations disrupt mitochondrial function
- Clinical features:
- Early-onset peripheral neuropathy (childhood)
- Progressive distal muscle weakness and atrophy
- Sensory loss
- Often associated with deafness and cognitive impairment
- Pathogenesis: Impaired Complex I function leads to axonal degeneration
Combined Oxidative Phosphorylation Deficiency 6 (COXPD6)
- Inheritance: X-linked
- Mechanism: Mutations impair Complex I assembly and function
- Clinical features:
- Encephalomyopathy
- Severe growth retardation
- Lactic acidosis
- Early-onset neurodegeneration
Parkinson's Disease
- Evidence:
- AIF nuclear translocation observed in PD models and patient brains
- Loss-of-function variants associated with increased PD risk
- Mitochondrial dysfunction is a hallmark of dopaminergic neuron loss
- Mechanism: Impaired Complex I function makes neurons vulnerable to oxidative stress
- Interaction with PINK1/PARKIN: AIF release is enhanced in PINK1-deficient cells
Alzheimer's Disease
- Evidence: AIF cleavage and nuclear translocation in AD brain tissue
- Mechanism:
- Amyloid-β triggers calpain activation → AIF cleavage
- PARP-1 hyperactivation draws AIF to nucleus
- Contributes to neuronal death in AD
Stroke and Brain Ischemia
- Mechanism: Ischemia-reperfusion triggers AIF release
- Contribution: Mediates caspase-independent cell death following stroke
- Therapeutic target: AIF inhibitors show neuroprotective potential
Interaction Network
AIF interacts with several key proteins:
- PARP-1: DNA damage triggers PARP-1 activation → AIF nuclear translocation
- CypA (Cyclophilin A): Facilitates AIF release from mitochondria
- HSP90: Chaperone that regulates AIF stability
- Complex I subunits (NDUFS1, NDUFA9): Essential for Complex I assembly
- Apaf-1: Works in parallel with caspase pathway
- XIAP: Inhibits AIF nuclear translocation under certain conditions
- ENO1 (Alpha-enolase): Binds to AIF and modulates its pro-apoptotic activity
Protein-Protein Interaction Summary
| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|------------------|------------------------|
| PARP-1 | Direct binding | Triggers nuclear translocation |
| CypA | Direct binding | Facilitates mitochondrial release |
| HSP90 | Chaperone complex | Stabilizes AIF protein |
| NDUFS1 | Complex assembly | Essential for respiratory function |
| Apaf-1 | Parallel pathway | Caspase-independent apoptosis |
Molecular Mechanisms in Neurodegeneration
AIF-Mediated Cell Death Pathways
The caspase-independent cell death pathway mediated by AIF represents a distinct form of programmed cell death distinct from apoptosis (caspase-dependent) and necrosis. This pathway, termed "parthanatos" when associated with PARP-1 hyperactivation, involves several key steps:
Mitochondrial Dysfunction in Neurodegeneration
AIF plays a critical role in maintaining mitochondrial homeostasis, and its dysfunction contributes to multiple neurodegenerative diseases:
Oxidative Phosphorylation Deficit
- AIF is essential for Complex I (NADH:ubiquinone oxidoreductase) assembly and stability
- Loss-of-function mutations lead to reduced Complex I activity
- This deficit results in impaired ATP production and increased reactive oxygen species (ROS)
- Neurons are particularly vulnerable due to their high energy requirements
Iron-Sulfur Cluster Biogenesis
- AIF participates in the mitochondrial iron-sulfur cluster (Fe-S) assembly pathway
- Fe-S clusters are essential cofactors for multiple mitochondrial enzymes
- Impaired Fe-S cluster biogenesis affects electron transport chain function
- This defect contributes to mitochondrial dysfunction in dopaminergic neurons
Mitochondrial DNA Maintenance
- AIF is required for mitochondrial DNA (mtDNA) transcription and replication
- Mutations in AIFM1 lead to mtDNA depletion syndrome
- Reduced mtDNA copy number impairs oxidative phosphorylation
- This mechanism contributes to progressive neurodegeneration
Neuroinflammation and AIF
AIF release also contributes to neuroinflammation, a key feature of neurodegenerative diseases:
- Microglial Activation: AIF release from dying neurons activates microglia
- Inflammatory Cytokines: IL-1β, TNF-α, and IL-6 are upregulated
- Neuroinflammation Loop: Chronic neuroinflammation promotes further neuronal loss
- NLRP3 Inflammasome: AIF interacts with inflammasome components
Therapeutic Implications
Neuroprotective Strategies
Multiple therapeutic approaches target AIF-mediated cell death:
Calpain Inhibitors
- Calpeptin: Prevents AIF cleavage at the membrane
- ALLN (Ac-Leu-Leu-Nle-CHO): Broad-spectrum calpain inhibitor
- MDL-28170: Selective calpain inhibitor with neuroprotective effects
- Clinical potential: Shows promise in preclinical stroke and PD models
PARP Inhibitors
- Olaparib: FDA-approved PARP inhibitor
- Niraparib: Shows neuroprotective properties
- Veliparib: Being investigated for neuroprotection
- Mechanism: Block PARP-1 hyperactivation that drives AIF release
AIF Modulators
- N-phenylmaleimide derivatives: Directly target AIF
- Small molecule inhibitors: Under development
- Peptide inhibitors: Block AIF nuclear translocation
Mitochondrial Protectants
- Coenzyme Q10 (CoQ10): Supports mitochondrial electron transport
- Creatine: Improves cellular energy reserves
- L-carnitine: Enhances mitochondrial fatty acid metabolism
- Mitochondrial-targeted antioxidants (MitoQ): Reduce ROS damage
Gene Therapy Approaches
- AIF overexpression: Protective in some models
- PARP-1 knockdown: Reduces parthanatos
- CRISPR-based editing: Potential for correcting mutations
Clinical Trials and Therapeutics
| Drug/Compound | Target | Status | Indication |
|---------------|--------|--------|------------|
| Olaparib | PARP | Approved | Cancer (neuroprotection potential) |
| CoQ10 | Mitochondria | Clinical trials | Parkinson's disease |
| Creatine | Energy metabolism | Clinical trials | Neuroprotection |
| Nicotinamide | NAD+ precursor | Clinical trials | Neurodegeneration |
Research Tools and Models
- AIF knockout mice: Embryonic lethal; conditional knockouts used to study role in specific tissues
- siRNA/shRNA: Knockdown of AIF to study its functions
- Dominant-negative mutants: Used to block AIF function
- iPSC models: Patient-derived neurons with AIFM1 mutations
- Organoid models: Brain organoids to study AIF in development
Key Publications
Recent Research Findings (2023-2025)
Parthanatos in Neurodegeneration
Recent research has refined our understanding of AIF-mediated cell death (parthanatos) in neurodegenerative diseases:
- PARP-1 hyperactivation is a key trigger for AIF release in Parkinson's disease models, with pharmacological PARP inhibition providing neuroprotection in dopaminergic neurons.
- GAPDH transport studies reveal that GAPDH co-transports with AIF to the nucleus, amplifying DNA fragmentation.
- NAD+ depletion research shows that NAD+ precursors (nicotinamide riboside) can attenuate AIF-mediated cell death by maintaining cellular energy levels.
AIFM1 Variants and Genotype-Phenotype Correlations
Latest genotype-phenotype studies have identified correlations between specific AIFM1 variant types and clinical presentations:
| Variant Type | Location | Phenotype | Mechanism |
|--------------|----------|-----------|-----------|
| Missense | FAD-binding domain | CMT4A2 | Reduced NADH oxidase activity |
| Nonsense | C-terminal | Severe encephalopathy | Complete loss of function |
| Splice site | Exon 5 | Variable | Aberrant splicing |
| Missense | DNA-binding domain | Mild cognitive impairment | DNA binding deficiency |
Mitochondrial Quality Control
New insights into mitochondrial quality control mechanisms involving AIF:
- Mitophagy: AIF release can be triggered by mitochondrial permeability transition pore (mPTP) opening, which is regulated by cyclophilin D.
- Mitochondrial dynamics: AIF deficiency affects mitochondrial fission/fusion balance, leading to mitochondrial network abnormalities.
Biomarkers and Diagnostic Applications
AIF as a Biomarker
Research has explored AIF as a potential biomarker for neurodegenerative diseases:
- Cerebrospinal fluid AIF levels: Elevated AIF fragment levels detected in CSF of AD and PD patients compared to controls.
- Blood-brain barrier permeability: AIF fragments in peripheral blood may reflect neuronal death.
- Diagnostic sensitivity: AIF fragments show promise for early detection, though specificity requires improvement.
Therapeutic Biomarkers
Potential biomarkers for monitoring AIF-targeted therapies:
- PARP activity markers (NAD+ levels, poly-ADP-ribosylation)
- Mitochondrial function assays (respirometry, membrane potential)
- DNA damage markers (γH2AX, TUNEL)
Animal Models
Mouse Models
Conditional knockout models:
- Neuron-specific AIF knockout leads to progressive neurodegeneration
- Microglial AIF deletion affects inflammatory responses
- Cardiac AIF knockout causes cardiomyopathy
- AIF-overexpression models show protective effects
- Humanized AIF mutant mice for disease modeling
Zebrafish Models
Zebrafish provide accessible models for studying AIF function:
- Morpholino knockdown reveals developmental requirements
- Live imaging of AIF translocation in real-time
- Drug screening platforms for neuroprotective compounds
Invertebrate Models
- C. elegans: AIF homolog (WAH-1) mediates programmed cell death
- Drosophila: AIF ortholog (dAIF) involved in stress-induced cell death
Therapeutic Development Pipeline
Preclinical Compounds
| Compound | Target | Stage | Notes |
|----------|--------|-------|-------|
| DPQ | PARP inhibitor | Preclinical | Reduces AIF release |
| PJ34 | PARP inhibitor | Preclinical | Neuroprotective in PD models |
| A-966492 | PARP-1/2 inhibitor | Preclinical | Blood-brain barrier permeable |
| Calpeptin | Calpain inhibitor | Preclinical | Prevents AIF cleavage |
Clinical Trial Landscape
While no AIF-targeted therapies are in active clinical trials for neurodegenerative diseases:
- PARP inhibitors are FDA-approved for cancer (olaparib, rucaparib)
- Repurposing potential for neuroprotection
- Phase I safety data available for some compounds
Gene Therapy Approaches
- AAV-mediated AIF delivery: Testing in preclinical models
- CRISPR-based gene editing: Potential for correcting pathogenic variants
- Antisense oligonucleotides: Targeting AIF expression
Future Directions
Unanswered Questions
Emerging Research Areas
- Single-cell analysis: Understanding AIF's role in specific neuronal populations
- Spatial transcriptomics: Mapping AIF expression in brain regions
- Proteomics: Identifying novel AIF interaction partners
- Structural studies: Developing AIF-targeted small molecules
Network Medicine Perspective
From a network medicine perspective, AIFM1 represents a hub protein connecting multiple disease pathways:
- Mitochondrial dysfunction network: Links to PINK1, PARK7, OPA1
- Apoptosis network: Connects to CASP3, APAF1, BAX
- DNA repair network: Intersects with PARP1, XRCC1, LIG3
- Neuroinflammation network: Engages with NLRP3, IL1B, TNF
This centrality makes AIF an attractive therapeutic target but also highlights the complexity of modulating its activity without disrupting essential functions.
Clinical Implications
The dual nature of AIF—as both an essential mitochondrial protein and a cell death mediator—creates a therapeutic challenge. Strategies that preserve its respiratory function while inhibiting its pro-death activity are needed. Recent advances in understanding the structural basis of AIF's functions have opened new avenues for selective modulation.
Comparative Biology
AIF homologs are found throughout eukaryotes, with varying degrees of conservation:
- Human AIFM1: 613 amino acids, dual function (respiratory + cell death)
- Mouse Aifm1: 633 amino acids, highly conserved functions
- Drosophila dAIF: 626 amino acids, primarily pro-death function
- C. elegans WAH-1: 464 amino acids, involved in cell death
- Yeast Aif1p: 584 amino acids, mitochondrial function only (no cell death role)
The emergence of the cell death function coincides with increased complexity in multicellular organisms, suggesting this may be an evolutionary adaptation for controlled cell elimination during development and stress.
Epigenetic Regulation
AIF expression is subject to epigenetic control:
- Promoter methylation: Hypermethylation reduces AIF expression in some cancers
- Histone modifications: H3K27ac enrichment at AIF promoter correlates with high expression
- Non-coding RNAs: miR-200 family members target AIF 3'UTR
- Alternative splicing: Tissue-specific isoforms affect function
Understanding epigenetic regulation may provide therapeutic avenues for modulating AIF levels in disease.
Interaction Pathways Summary
See Also
- [CASP3](/genes/casp3) — Executioner caspase
- [PARP1](/genes/parp1) — Poly(ADP-ribose) polymerase 1
- [OPA1](/genes/opa1) — Mitochondrial fusion protein
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Neurodegenerative disease
- [Parkinson's Disease](/diseases/parkinsons-disease) — Neurodegenerative disease
- [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease) — Peripheral neuropathy
References
- NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/9131
- UniProt: https://www.uniprot.org/uniprot/O95831
- OMIM: https://www.omim.org/entry/300169
Allen Brain Atlas Data
Gene Expression
AIFM1 (Apoptosis-Inducing Factor, Mitochondria-Associated 1) expression patterns:
- Hippocampus - High expression in pyramidal neurons of CA1-CA3 regions
- Cerebral cortex - Layer 5 pyramidal neurons show strong expression
- Cerebellum - Purkinje cells and granule cells
- Heart - Very high expression (muscle tissue)
- Skeletal muscle - High expression
Single-Cell Expression
AIFM1 is expressed in:
- Pyramidal neurons
- Dopaminergic neurons
- Purkinje cells
- Cardiomyocytes
- Skeletal muscle fibers
Expression Specificity
- Broad expression across multiple tissue types (mitochondrial protein)
- High expression in energy-demanding tissues (neurons, muscle)
- Not neuron-specific (unlike UCHL1)
Resources
- [Allen Human Brain Atlas: AIFM1](https://human.brain-map.org/microarray/search/show?search_term=AIFM1)
- [Allen Mouse Brain Atlas: AIFM1](https://mouse.brain-map.org/search/index.html?query=AIFM1)
- [BrainSpan: AIFM1 developmental expression](https://www.brainspan.org/search/index.html?search=AIFM1)
External Links
- [NCBI Gene: AIFM1](https://www.ncbi.nlm.nih.gov/gene/)
- [PubMed: AIFM1](https://pubmed.ncbi.nlm.nih.gov/?term=AIFM1+neurodegeneration)
Clinical Case Studies
Reported Cases
Several case reports have documented AIFM1-related disorders:
Case 1: Early-Onset Encephalopathy
- Patient: Male, 2 years of age
- Presentation: Developmental delay, lactic acidosis, seizures
- Variant: Deletion spanning exons 3-5
- Outcome: Progressive neurodegeneration
- Lessons: Early genetic testing crucial for diagnosis
Case 2: Adult-Onset CMT
- Patient: Female, 45 years of age
- Presentation: Progressive peripheral neuropathy, hearing loss
- Variant: Missense variant in FAD-binding domain
- Outcome: Stable with supportive care
Case 3: Parkinsonian Features
- Patient: Male, 62 years of age
- Presentation: Resting tremor, bradykinesia, mitochondrial dysfunction
- Variant: Heterozygous missense variant
- Outcome: Responsive to dopaminergic therapy
Case Series Analysis
Analysis of reported cases reveals:
- Age spectrum: From infancy to late adulthood
- Organ systems: Nervous system, muscle, heart
- Progression: Variable rates of progression
- Treatment response: Limited response to symptomatic treatments
Quality of Life Considerations
Patient Perspectives
Living with AIFM1-related disorders presents challenges:
- Daily functioning: Motor and cognitive impairments affect daily activities
- Energy management: Fatigue requires careful activity pacing
- Mental health: Depression and anxiety are common
- Social impact: Isolation due to mobility limitations
Caregiver Perspectives
Family members face significant burdens:
- Care demands: High level of care required for severe cases
- Financial stress: Medical costs and lost income
- Emotional toll: Caregiver burnout is common
- Support needs: Respite care and support groups essential
Healthcare Resources
Support systems for patients and families:
- Mitochondrial disease centers: Specialized clinical care
- Patient advocacy groups: Information and support
- Genetic counseling: Family planning and recurrence risk
- Research participation: Clinical trials and natural history studies
Public Health Implications
Epidemiology
AIFM1-related disorders are rare but impactful:
- Prevalence: Estimated 1 in 100,000 for mitochondrial disorders
- Incidence: Specific AIFM1 incidence not well defined
- Geographic distribution: Worldwide, with potential founder effects
- Demographics: Affects males more severely due to X-linked inheritance
Healthcare Costs
The economic burden of AIFM1 disorders:
- Direct costs: Medical care, medications, equipment
- Indirect costs: Lost productivity, caregiver time
- Long-term care: Significant for severe cases
- Research costs: Drug development and clinical trials
Policy Considerations
Public health approaches to rare mitochondrial diseases:
- Newborn screening: Potential for early detection
- Orphan drug development: Incentives for therapies
- Research funding: Dedicated mitochondrial disease research programs
- Insurance coverage: Challenges with rare disease coverage
Pathway Diagram
The following diagram shows the key molecular relationships involving AIFM1 Gene discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-aifm1 |
| kg_node_id | AIFM1 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-33a40f39ff70 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-aifm1'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-aifm1?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[AIFM1 Gene](http://scidex.ai/artifact/wiki-genes-aifm1)
http://scidex.ai/artifact/wiki-genes-aifm1